AC Immune SA (ACIU)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in AC Immune SA, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

AC Immune SA (ACIU) has returned -12.42% so far this year and 47.06% over the past 12 months.

Based on dividend-adjusted daily data since Sep 23, 2016, ACIU's average daily return is +0.06%, while the average monthly return is +0.16%. At this rate, your investment would double in approximately 36.1 years.

Historically, 47% of months were positive and 53% were negative. The best month was May 2024 with a return of +87.5%, while the worst month was Jan 2019 at -56.4%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 9 months.

On a daily basis, ACIU closed higher 46% of trading days. The best single day was Jun 27, 2023 with a return of +71.7%, while the worst single day was Jan 30, 2019 at -66.0%.

AC Immune SA has an annualized alpha of 1.87%, beta of 0.96, and R² of 0.05 versus S&P 500 Index. Calculated based on daily prices since September 26, 2016.

• This stock participated in 176.60% of S&P 500 Index downside but only 66.37% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.05 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ACIU ranks 63 for risk / return — better than 63% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for AC Immune SA (ACIU) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the AC Immune SA. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the AC Immune SA was 92.33%, occurring on Apr 10, 2025. The portfolio has not yet recovered.

The current AC Immune SA drawdown is 85.75%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of AC Immune SA over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how AC Immune SA is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.